Novel neuronal targets for the acetylcholinesterase inhibitor donepezil

Neuropharmacology

Volumn 47, Issue 8, 2004, Pages 1198-1204

  Sortino, M A ^a   Frasca, G ^a   Chisari, M ^a   Platania, P ^a   Chiechio, S ^a   Vancheri, C ^a   Copani, A ^a   Canonico, P L ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Alzheimer's disease; Apoptosis; Cell cycle; Differentiation

Indexed keywords

CHOLINESTERASE INHIBITOR; CYCLIN B; CYCLIN E; CYCLINE; DONEPEZIL; GALANTAMINE; MICROTUBULE ASSOCIATED PROTEIN 2; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PROTEIN P21;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR MIMICRY; NERVE CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; INDANS; NEURONS; PIPERIDINES;

EID: 9644301088     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.08.011     Document Type: Article

References (42)

1. Arias E., Alés E., Gabilan N.H., Cano-Abad N.F., Villaroya M., Garcia A.G., Lopez M.G. Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology. 46:2004;103-114
2. Barnes C.A., Meltzer J., Houston F., Orr G., McGann K., Wenk G.L. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience. 99:2000;17-23
3. Blagosklonny M.V. Apoptosis, proliferation, differentiation: in search of the order. Semin. Cancer Biol. 13:2003;97-105
4. Busser J., Geldmacher D.S., Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J. Neurosci. 18:1998;2801-2807
5. Copani A., Condorelli F., Caruso A., Vancheri C., Sala A., Canonico P.L., Nicoletti F., Sortino M.A. Mitotic signaling by β-amyloid peptide causes neuronal death. FASEB J. 13:1999;2225-2234
6. Copani A., Caricasole A., Caruso A., Caraci F., Iacovelli L., Sortino M.A., Terstappen G.C., Nicoletti F. The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol. Sci. 24:2003;233-238
7. dos Santos A.A., Medina S.V., Sholl-Franco A., de Araujo E.G. PMA decreases the proliferation of retinal cells in vitro: the involvement of acetylcholine and BDNF. Neurochem. Int. 42:2003;73-80
8. Fucile S., Napolitano M., Mattei E. Cholinergic stimulation of human microcytoma cell line H69. Biochem. Biophys. Res. Commun. 230:1997;501-504
9. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann. N. Y. Acad. Sci. 920:2000;321-327
10. Grana X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:1995;211-219
11. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816
12. Hellstrom-Lindahl E., Moore H., Nordberg A. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J. Neurochem. 74:2000;777-784
13. Husseman J.W., Nochlin D., Vincent I. Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases. Neurobiol. Aging. 21:2000;815-828
14. Kato K., Hayako H., Ishihara Y., Marui S., Iwane M., Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci. Lett. 260:1999;5-8
15. La Sorella A., Iavarone A., Israel M.A. Differentiation of neuroblastoma enhances bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res. 55:1995;4711-4716
16. Lombet A., Zujovic V., Kandouz M., Billardon C., Carvajal-Gonzales S., Gompel A., Rostène W. Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation. Role of bcl-2 protein family. Eur. J. Biochem. 268:2001;1352-1362
17. Lukas R.J., Norman S.A., Lucero L. Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. Mol. Cell. Neurosci. 4:1993;1-12
18. Maelicke A., Schrattenholz A., Samochocki M., Radina M., Albuquerque E.X. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav. Brain Res. 113:2000;199-206
19. McShea A., Harris P.L., Webster K.R., Wahl A.F., Smith M.A. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am. J. Pathol. 150:1997;1933-1939
20. McShea A., Wahl A.F., Smith M.A. Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease. Med. Hypotheses. 52:1999;525-527
21. Metzen J., Bittinger F., Kirkpatrick C.J., Kilbinger H., Wessler I. Proliferative effect of acetylcholine on rat trachea epithelial cells is mediated by nicotinic receptors and muscarinic receptors of the M1-subtype. Life Sci. 72:2003;2075-2080
22. Nagy Z., Esiri M.M., Cato A.M., Smith A.D. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol. (Berl.). 94:1997;6-15
23. Nordberg A., Svensson A.-L. Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology. Drug Saf. 19:1998;465-480
24. Racchi M., Sironi M., Caprera A., Konig G., Govoni S. Short and long-term effects of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol. Psychiatry. 6:2001;520-528
25. Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 179:2002;1-14
26. Ross R.A., Spengler B.A., Biedler J.L. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J. Natl. Cancer Inst. 71:1983;741-747
27. Santos M.D., Alkondon M., Pereira E.F., Aracava Y., Eisenberg H.M., Maelicke A., Albuquerque E.X. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol. Pharmacol. 61:2002;1222-1234
28. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 49:1996;1-6
29. Snape M.F., Misra A., Murray T.K., De Souza R.J., Williams J.L., Cross A.J., Green A.R. A comparative study in rats of the in vitro and in vivo pharmacology of acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology. 38:1999;181-193
30. Song P., Sekhon H.S., Jia Y., Keller J.A., Blusztajn J.K., Mark G.P., Spindel E.R. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res. 63:2003;214-221
31. Steel M.C., Buckley N.J. Differential regulation of muscarinic receptor mRNA levels in neuroblastoma cells by chronic agonist exposure: a comparative polymerase chain reaction study. Mol. Pharmacol. 43:1993;694-701
32. Svensson A-L., Nordberg A. Interaction of tacrine, galanthamine, NXX-066 and E2020 with neuronal a4β2 nicotinic receptors expressed in fibroblast cells. Iqbal K., Winblad B., Nishimura T., Takeda M., Wisniewski H.M. Alzheimer's Disease: Biology, Diagnosis and Therapeutics. 1997;753-758 John Wiley & Sons Ltd, New York
33. Svensson A.L., Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of Aβ(25-35) in rat PC12 cells. Neuroreport. 9:1998;1519-1522
34. Takada Y., Yonezawa A., Kume T., Katsuki H., Keneko S., Sugimoto H., Akaike A. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cotical neurons. J. Pharm. Exp. Ther. 306:2003;772-777
35. Vincent I., Rosado M., Davies P. Mitotic mechanisms in Alzheimer's disease? J. Cell Biol. 132:1996;413-425
36. Vincent I., Jicha G., Rosado M., Dickson D. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J. Neurosci. 17:1997;3588-3598
37. Wang X.D., Zhang J.M., Yang H.H., Hu G.Y. Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Acta Pharmacol. Sin. 20:1999;21-35
38. Williams C.L. Muscarinic signaling in carcinoma cells. Life Sci. 72:2003;2173-2182
39. Woodruff-Pak D.S., Vogel R.W., Wenk G.L. Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors. Neuroscience. 117:2003;439-447
40. Yang Y., Mufson E.J., Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J. Neurosci. 23:2003;2557-2563
41. Zhang H.Y., Tang X.C. Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells. Neurosci. Lett. 292:2000;41-44
42. Zhou J., Fu Y., Tang X.C. Huperazine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci. Lett. 306:2001;53-56